- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 24.10. | CPHI Europe: how AI can drive growth in the nutraceutical space | ||
| 24.10. | CPHI Europe: strategies to navigate nitrosamines risk evaluation | ||
| 24.10. | Global conflicts prompt GPEI to delay polio eradication target | ||
| 24.10. | How supervised machine learning optimizes AI use in clinical trials | ||
| 24.10. | DPV set to acquire Lumos Pharma for $38m | ||
| 24.10. | TreeFrog and University of Pittsburgh probe TLS role in immuno-oncology | ||
| 24.10. | Be Bio raises $82m to advance haemophilia B gene therapy to Phase I/II trial | ||
| 24.10. | Lilly's Kisunla does not demonstrate "good value" for UK's NHS | ||
| 23.10. | FDA expands Pfizer's RSV vaccine label to include all high-risk adults | ||
| 23.10. | Ocuphire Pharma and Opus Genetics merge to develop IRD gene therapy | ||
| 23.10. | FDA approves Alvotech and Teva's SELARSDI for new indications | ||
| 23.10. | AAO 2024: NMA reveals Vabysmo's superior CST improvement over Eylea HD | ||
| 23.10. | Health Canada approves Servier's VORANIGO for IDH-mutant glioma | ||
| 23.10. | A slow start for self-amplifying mRNA vaccines | ||
| 22.10. | Gilead and MSD to advance once-weekly HIV treatment to Phase III | ||
| 22.10. | Editas and Genevant team up to develop gene editing therapies | ||
| 22.10. | World Osteoporosis Day calls for urgent action to prevent fragility fractures | ||
| 22.10. | MangoRx hits back at Eli Lilly's weight loss drug copycat claims | ||
| 22.10. | How pharma leaders are approaching digital transformation | ||
| 22.10. | Navigating clinical trial disruption: growing trends and new technologies | ||
| 22.10. | Avacta partners Tempus AI to boost cancer therapy development | ||
| 22.10. | EU CHMP recommends AstraZeneca and Ionis' Wainzua for ATTRv-PN | ||
| 22.10. | Cambridge University and GSK sign immunology R&D collaboration | ||
| 21.10. | AAO 2024: Nanoscope Therapeutics" MCO-010 RESTOREs vision in RP patients | ||
| 21.10. | Sanofi's $17bn sale of Opella to US investors advances following government deal |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
